Fibroblast growth factors are essential molecules for development. Here we characterize Fgf17, a new member of the ®broblast growth factor (FGF) family. The Fgf17 gene maps to mouse chromosome 14 and is highly conserved between mouse and human (93% identity). It exhibits 60% amino acid identity with Fgf8 and 50% identity with Fgf18. Both Fgf8 and Fgf17 have a similar structure and a similar pattern of alternative splicing in the 5 H coding region. When expressed in 3T3 ®broblasts, mouse FGF17 is transforming, indicating that it can activate the`c' splice form of either FGF receptor (FGFR) one or two. During midgestation embryogenesis, in situ hybridization analysis localized Fgf17 expression to speci®c sites in the midline structures of the forebrain, the midbrain-hindbrain junction, the developing skeleton and in developing arteries. Comparison to Fgf8 revealed a striking similarity in expression patterns, especially in the central nervous system (CNS), suggesting that both genes may be important for CNS development, although Fgf17 is expressed somewhat later than Fgf8. In the developing skeleton, both genes are expressed in costal cartilage while Fgf8 is preferentially expressed in long bones. In the developing great vessels Fgf17 is preferentially expressed, suggesting that it may have a more prominent role in vascular growth. q
Introduction
Fibroblast growth factors (FGFs) comprise a growing family of secreted proteins that have both unique and redundant roles in many developmental processes. In early embryogenesis, FGFs have been shown to modulate embryonic mesoderm growth and migration, while during later development FGFs regulate cellular growth and differentiation. In some cases, FGF signaling occurs autonomously within a tissue, while in other cases, FGFs signal directionally across epithelial-mesenchymal boundaries. The diverse roles of FGFs in development depend upon the distinct expression patterns of both ligands and receptors and on speci®c binding interactions with alternatively spliced receptors.
A variety of experimental approaches have provided compelling evidence for FGF signaling during development. For example, in mouse embryos lacking Fgf4, blastocyst growth and implantation fails to occur (Feldman et al., 1995) suggesting an essential role for FGF signaling in very early embryonic development. Similarly, Fgf8 null mice die by E9.5 lacking all embryonic mesoderm-derived structures (Meyers et al., 1998) . Interfering with FGF receptor activity in Xenopus embryos inhibits posterior mesoderm development (Amaya et al., 1991) and mouse embryos homozygous for a null allele of Fgfr1 have defective axial mesoderm migration (Deng et al., 1994; Yamaguchi et al., 1994) . These experiments demonstrate the importance of FGF signaling in vertebrate axis formation.
An inductive role of FGF is demonstrated by experiments in which FGF-soaked beads, implanted at various embryonic sites, induce the development of speci®c embryonic structures. For example, exogenously applied FGF8 can induce ectopic midbrains (Crossley et al., 1996a) or ectopic limbs (Crossley et al., 1996b) , suggesting a role for FGFs in mediating midbrain organizer function and in initiating the embryonic limb bud. Later in development, FGF signaling can regulate cell growth, differentiation and migration. For example, a homozygous null mutation in the Fgfr3 gene causes overgrowth of long bones in mice Deng et al., 1996) while constitutively active forms of FGFR3 result in dwar®sm (Shiang et al., 1994; Naski et al., 1996; . These observations suggest that FGF signaling is a negative regulator of endochondrial bone growth. Fibroblast growth factors can also regulate and delay the differentiation of muscle precursor cells both in vitro and in vivo (Olwin and Hauschka, 1988; Itoh et al., 1996) . Fibroblast growth factor signaling is essential for migration of sex myoblasts in C. elegans (DeVore et al., 1995) , of tracheal cells in Drosophila (Beiman et al., 1996) and of skeletal muscle precursor cells in chick (Itoh et al., 1996) . Similarly, migration of rat oligodendrocyte progenitor cells into brain parenchyma can be speci®cally blocked when induced to express a dominant negative FGFR (Osterhout et al., 1997) .
Despite these advances in our understandings of the role of FGF signaling in development, little is known about speci®c pairs of interacting FGF ligands and receptors in vivo. Fibroblast growth factors are a family of at least 18 structurally-related signaling proteins (Coulier et al., 1997; McWhirter et al., 1997; Greene et al., 1998; Miyake et al., 1998; Ohbayashi et al., 1998; Yamamoto et al., 1998) . Most Solid boxes indicate sequences common to all splicing isoforms and shaded boxes represent alternatively used coding sequence. Arrows indicate the position of primers used for RT-PCR identi®cation of alternative splicing. Fgf17 genomic structure is shown at the top followed by three alternatively spliced cDNA isoforms, 17a, 17b and 17c. *Indicates a stop codon in the extended region of exon lB. Fgf8 genomic structure is shown at the bottom followed by the 8b splice form. members of this family are able to bind and activate at least one of four transmembrane tyrosine kinase receptors. Binding speci®city is also dramatically affected by tissue-speci®c alternative splicing of FGF receptors . Additionally, FGFs bind heparan sulfate polysaccharides which modulate their interactions with high af®nity receptors (Rapraeger et al., 1991; Yayon et al., 1991; Ornitz and Waksman, 1997) .
Because FGFs act over short ranges, potential developmentally relevant ligand receptor pairs can be identi®ed by examining the expression patterns of FGF ligands and receptors and by determining the ligand binding speci®city towards speci®c receptors. Additionally, the identi®cation of new members of the FGF family may suggest novel roles for FGF signaling during development, identify redundant function between ligands and ®ll gaps where FGF signaling is postulated to occur but where a ligand has not been identi®ed. Recently, Fgf17 and Fgf18 have been identi®ed and shown to be most closely related to Fgf8 Ohbayashi et al., 1998) . Additionally, during early mouse development these genes partially overlap in their pattern of expression (Maruoka et al., 1998) . In this work, we report the cloning, gene structure, mapping and activity of Fgf17. Additionally, comparison of the expression pattern of Fgf8 and Fgf17 throughout mouse organogenesis revealed signi®cant overlap as well as spatial and temporal differences in embryonic brain, bone and arteries. These data suggest a role for both Fgf8 and Fgf17 in patterning the embryonic brain and in regulating osteogenesis and vascular development. Also identi®ed is a novel expression pattern for Fgf8 in developing long bone and cartilage, suggesting that Fgf8 may be involved in the development of these tissues.
Results

Cloning murine ®broblast growth factor 17
The Fgf17 gene was identi®ed by sequence homology in a human ovarian expressed sequence tag (EST) library (Greene et al., 1998) . Based on the sequence of this human EST and its observed expression in adult human brain, a PCR primer pair located in the predicted third exon (based on the conserved layout of exons among other FGF family members) was used to amplify a 155-bp DNA fragment using mouse brain cDNA as the template. The ampli®ed DNA fragment showed 93% identity to the human Fgf17 cDNA and 100% identity to the rat Fgf17 cDNA, indicating that the murine homologue had been identi®ed (Greene et al., 1998; Hoshikawa et al., 1998) . Additional primers were synthesized and used to amplify the entire coding region (see Section 4). Sequence alignment indicates that Fgf8, 17 and 18 comprise a sub family of Fgfs more closely related to each other than to other members of the Fgf family (Fig. 1A,B) (MacArthur et al., 1995b; Greene et al., 1998; Hoshikawa et al., 1998; Ohbayashi et al., 1998) .
The Fgf17 genomic locus was cloned to facilitate genetic mapping and to permit a comparative analysis of the gene structure between Fgf8 and Fgf17. Polymerase chain reaction primers were used to identify a genomic P1 clone (Genome Systems, Inc., St. Louis, MO) and subclones were then identi®ed by hybridization with cDNA probes.
The genomic structure of Fgf17 was determined by sequencing coding exons and intron-exon boundaries (Fig. 1C) . Exon sequences derived from genomic subclones were also used to con®rm the cDNA sequence derived by RT-PCR.
The Fgf8 gene has multiple alternatively spliced cDNA isoforms encoded by four small exons in the 5 H part of the gene (Crossley and Martin, 1995; MacArthur et al., 1995b) . Similar to Fgf8, the 5 H coding region of the Fgf17 gene is divided into three small exons (Fig. 1C) . In contrast, most other members of the FGF family encode the 5 H region within a single exon. The three 5
H exons of mouse Fgf17 correspond to exons lA, B and D of Fgf8. However, the sizes of most of the introns in the Fgf17 gene are different from those of Fgf8 (Fig. 1C) . The similarities in both sequence and gene structure suggest that Fgf8 and Fgf17 may have arisen by an evolutionary gene duplication event.
To determine whether the Fgf17 gene is also alternatively spliced, embryonic day 11.5 mouse RNA was ampli®ed by RT-PCR using a forward primer derived from exon lA sequence and a reverse primer derived from exon 1D (Fig.  1C, top) . Ampli®ed fragments were cloned and sequenced and found to encode three alternatively spliced cDNA isoforms (Fig. 1C, middle) . The three alternatively spliced isoforms of Fgf17 all have similar counterparts among the eight reported Fgf8 cDNA isoforms (Crossley and Martin, 1995; MacArthur et al., 1995b) . Sequence corresponding to exon 1C of the Fgf8 gene has thus far not been identi®ed in the Fgf17 gene. Interestingly, one of the isoforms of Fgf17, Fgf17c, has a stop codon in the extended region of exon lB, suggesting that it does not encode a functional protein.
2.2. FGF8 and FGF17 have similar activity and receptor speci®city NIH3T3 cells express FGF receptors 1 and 2, and have been used to test the biological activities of FGFs in vitro (Rogelj et al., 1988) . Fibroblast growth factors that can activate`c' splice forms of FGF receptor one or two can transform NIH3T3 cells and the resulting cells form tumors when injected into mice (Rogelj et al., 1988) . To determine whether the Fgf17 gene encodes an active signaling molecule, NIH3T3 cells were stably transfected with a selectable expression vector for FGF17a, FGF17b, FGF8b or empty vector. Ribonucleic acid blot analysis con®rmed the expression of exogenous FGFs in the transfected cells ( Fig. 2A) . Pooled, selected cells were then examined for morphologic changes. Cells expressing either FGF8b or FGF17b adopted a transformed morphology. The cells were spindle-shaped and loosely attached to the culture dish (Fig. 2B) . To con®rm the transformed nature of these cells, nude mice were injected with 1 £ 10 6 cells derived from each of the stably selected pools (Table 1 ). All mice (®ve of ®ve) receiving cells transfected with Fgf8b developed a tumor after 1 week. Forty percent of mice (two of ®ve) receiving cells transfected with Fgf17b developed a tumor after 1 week and all developed a tumor after 2 weeks. The slower growth of tumors in mice injected with Fgf17b-transfected cells compared to Fgf8b-transfected cells may be due to a lower level of expression of Fgf17b ( Fig. 2A ). Fgf17a-transfected cells and cells transfected with empty vector did not show an altered morphology and did not form tumors when injected into nude mice. It is interesting that Fgf17a showed no activity in this assay, because the corresponding splice form of Fgf8, Fgf8a, also shows no activity towards the four known FGF receptors (MacArthur et al., 1995b; Blunt et al., 1997) . Together, these data demonstrate that mouse FGF17b encodes a protein of similar activity to FGF8b. Mitogenic analysis of recombinant human FGF17b on FGFR-expressing BaF3 cell lines shows that it has a similar receptor speci®city to FGF8b, activating FGFR2c, 3c and 4 but not FGFR1 (Greene et al., 1998) .
Fgf17 maps to mouse chromosome 14
The chromosomal location of murine Fgf17 was mapped by analyzing an interspeci®c backcross panel (BSS) derived from C57BL/6J and SPRET/Ei mice. An XbaI restriction site polymorphism within a 2-kb genomic PCR ampli®ca-tion fragment was identi®ed between genomic DNA from these strains (see Section 4). Based on the XbaI digestion patterns, the segregation of Fgf17 alleles in the 94 offspring of the BSS backcross panel were used to calculate the recombination frequency with adjacent loci (Rowe et al., 1994) . The results indicated that Fgf17 is located on the central portion of mouse chromosome 14 (Fig. 3A) , cosegregating with a recessive mutation, hairless (hr), the gene encoding the erythrocyte membrane skeleton protein dematin (Epb4.9) and two other physical markers, Dl4Birl2 and D14Birl4 (Fig. 3B) . No candidate mouse mutations map to this region.
Differential expression of Fgf8 and Fgf17 in embryonic facial ectoderm, forebrain and the midbrain-hindbrain junction
Both Fgf8 and Fgf17 expression were observed in the dorsal midline of the embryonic forebrain (commissural Fgf8 is expressed in the anterior neural ridge (anr) and in the midbrain-hindbrain junction (m/h) while Fgf17 is only detected in the midbrain-hindbrain junction. (E,F) both Fgf8 and Fgf17 are expressed in the anterior midline of the telencephalon at E9.5. Fgf8 but not Fgf17 is also expressed in the nasal epithelial primordium (arrowheads). (H,I) at E11.5 Fgf8 and Fgf17 expression are observed in the septal neural epithelium (se) and telencephalon-diencephalon junction (arrowhead). Fgf8 but not Fgf17 expression is also detected in the dorsal diencephalon (arrow), hypothalamus (hp) and infundibular recess (inf). di, diencephalon; te, telencephalon. plate) between embryonic day 9.5 and 10.5 (Maruoka et al., 1998 and data not shown). To compare the onset of Fgf8 and Fgf17 expressions in this tissue, embryonic day 8.5 coronal sections were examined by in situ hybridization. Signi®cant expression of Fgf8 was detected as two symmetrical bilateral signals at the rostral edge of the neural plate (Fig. 4A,  B) . This is consistent with previously published whole mount in situ hybridization data (Ohuchi et al., 1994; Crossley and Martin, 1995) . The rostral edge of the neural fold, often referred to as the anterior neural ridge (anr), contributes to the ontogeny of the olfactory placode, nasal epithelium and dorsal structures of the telencephalon (Couly and Le Douarin, 1985; Couly and Le Douarin, 1987) . However, Fgf17 expression in this region is not readily detected until E9.5 when both genes are expressed in a similar pattern and intensity at the commissural plate of the telencephalon (Fig.  4D±F) , suggesting that Fgf17 expression in this tissue is initiated later than that of Fgf8. At E11.5 (Fig. 4G±I ) and E12.5 (data not shown), both genes continue to be expressed in the midline structures of the telencephalon such as the septal neural epithelium.
The second domain of Fgf8 and Fgf17 expression in the forebrain is localized to the dorsal midline of the diencephalon. Signals for both genes become detectable around E9.5 (data not shown) and persist until at least E12.5. Interestingly, Fgf17 expression is restricted to a small domain at the transition between the dorsal telencephalon and diencephalon, whereas Fgf8 is more broadly expressed along the dorsal midline of the diencephalon (Fig. 4G±I and arrow and arrowheads in H and I) . In addition, Fgf8 is also expressed in ventral hypothalamic structures from E9.5 to E12.5 (Fig.  4H, I and data not shown), including the mamillary recess and infundibular recess. However, no Fgf17 expression is detected in this region throughout the stages analyzed. In the nasal epithelial primordium at E9.5 and at later stages, Fgf8 but not Fgf17 expression is detected (Fig. 4E , F arrowheads, and data not shown).
The midbrain-hindbrain junction is a developmentally important structure known to express Fgf8, 17 and 18 and thought to require FGF signaling for patterning and growth of the future midbrain-hindbrain structures (Crossley et al., 1996a; Maruoka et al., 1998) . Comparison of Fgf8 and Fgf17 expression at E9.5 and E10.5 shows similar intensities and pattern in the midbrain-hindbrain junction (Maruoka et al., 1998) . In extending this analysis to both earlier and later stages, we have identi®ed some signi®cant spatial and temporal differences between Fgf8 and Fgf17 expression. For example, at E8.5 (Fig. 4B, C) , Fgf8 is expressed more broadly and at much higher levels than Fgf17. In contrast, at E11.5 and E12.5, Fgf17 expression is consistently stronger and broader than that of Fgf8 (Fig.  5A±F) . Signi®cantly, at E13.5 (data not shown) and E14.5 (Fig. 5H, I ), only Fgf17 could be detected at the midbrainhindbrain junction, although its domain had narrowed and the signal was weaker. By E15.5, Fgf17 mRNA was undetectable (data not shown).
Fgf8 and Fgf17 expression in arteries
Fgf17 expression was observed throughout the wall of all major arteries including the aortic trunk, the brachiocephalic artery, the pulmonary arteries and the descending aorta from E12.5 to E16.5 (Fig. 6B, D, F, I, L, O) . The strongest signals were observed in the aortic (Fig. 6I ) and pulmonary trunks (not shown) and weaker signals were observed in ) at E15.5, both Fgf8 and Fgf17 mRNA are detected in the great arteries and pericardium (arrowhead). By E16.5, only Fgf17, but not Fgf8 mRNA, can be detected in the descending aorta (K,L) and the Fgf8 signal is weak compared to that of Fgf17 in the pulmonary arteries (arrows, N,O). ara, auricular part of left atrium; li, liver; lu, lung; r, rib; ra, right atrium; rv, right ventricle; rpa, right pulmonary artery; ve, vertebral column. peripheral arteries such as the branches of the right pulmonary artery (Fig. 6O) . No signal was detected in veins at any of the stages examined.
From E12.5 to E15.5, Fgf8 was also detected in all major arteries although the signal was consistently weaker than that of Fgf17 (Fig. 6C, F, H) . By E16.5, Fgf8 expression was not detectable in the descending aorta and weakly detectable in the branches of the pulmonary artery (Fig.  6K, N) . The observation that peripheral arteries expressed lower levels of Fgf8 and Fgf17 than great vessels and that Fgf8 and Fgf17 appeared to be expressed throughout the entire wall of the great vessels suggested that the expression originated in vascular smooth muscle cells (VSMCs) rather than in the endothelium. The consistently higher levels of Fgf17 expression suggest that this FGF may have a dominant role in arterial development.
Fgf8 and Fgf17 expression during skeletal development
FGF signaling is essential for both intramembranous and endochondral bone formation as demonstrated by numerous mutations in Fgfrs that affect skeletal development (reviewed in . However, the FGF ligand(s) required for normal bone growth and development are not known. During the course of these studies, both Fgf8 and Fgf17 were found to be expressed throughout the developing skeleton. Expression was ®rst detected in the dorsal costal cartilage at E14.5 when ossi®cation centers are ®rst seen (Fig. 7B, C) . The signal was strongest in the periosteum but also detectable within costal chondrocytes. By E15.5, Fgf8, and to a lesser extent Fgf17, were expressed in the periosteum of the dorsal part of the rib but not in the ventral costal cartilage (Fig. 7E±H ). This pattern of expression correlates with the dorsal to ventral pattern of ossi®ca-tion along the rib axis. In addition to the early expression in developing ribs, Fgf8 expression was also observed in the osteoblast compartment of calvarial bone (not shown), in the mandible (Fig. 7I, J) and in cortical bone and the growth plate of developing long bones (Fig. 7K, L) . Fgf17 expression was not detected in long bones but was detected in some intramembranous bone such as the maxilla (not shown) and the scapula (Fig. 7M, N) . By E16.5, when most ossi®cation centers have been established, the signals for both Fgf8 and Fgf17 mRNA became dif®cult to detect (not shown). The decreased expression at later stages of skeletal development suggests that these two genes are expressed in immature and differentiating osteoblast progenitor cells rather than in terminally differentiated cells. The peak levels of expression observed at E15.5 may re¯ect the rapid expansion of osteoblast progenitor cells at this stage of development.
Discussion
The Fgf17 and 18 genes comprise a subfamily of FGFs most closely related to Fgf8. Here we have shown that Fgf8 and Fgf17, which share 60% amino acid identity, have a similar gene structure, receptor binding speci®city and pattern of expression throughout embryonic development. The similarity between these two genes suggests that they have arisen by gene duplication. Interestingly, several other members of the FGF family appear to be grouped by sequence similarity and biochemical function. Most notably, Fgf7 and Fgf10 share 48% amino acid identity, both recognize the`b' splice form of FGF receptor 2 with high speci®city and both genes are expressed in tissues of mesenchymal origin Beer et al., 1997; A. Blunt, unpublished data) . Similarly, FGFs 1 and 2 and FGFs 4 and 6 appear paired and share similar biochemical properties Coulier et al., 1997) (Fig.  1A) .
The partial overlap in the expression pattern of Fgf8 and Fgf17 and the ability of both FGFs to activate FGF receptor 2c and 3c suggest that these FGFs may be redundant in function or have cumulative affects on target tissue. Even though the expression pattern of Fgf8 and Fgf17 show signi®cant similarity, distinct differences in expression appear to have evolved between these two genes. Several tissues express Fgf8 but completely lack Fgf17 (AER and branchial arches, data not shown), while other tissues express Fgf17 but not Fgf8 (midbrain-hindbrain junction at E14.5). These differences in expression patterns and the precise conservation of the mouse and human homologues suggest that unique functions have evolved for Fgf8 and Fgf17 and have been conserved throughout mammalian evolution.
Regulation of CNS development by FGFs
At least three lines of evidence suggest that FGF signaling is an essential mediator of midbrain-hindbrain organizer activity. First, an FGF8-soaked bead can induce ectopic midbrain formation in chick embryos when implanted in the caudal diencephalon (Crossley et al., 1996a) and second, ectopic expression of Fgf8 at the midbrain-hindbrain junction in transgenic mice can posteriorize the midbrain by inducing ectopic engrailed 2 (En2) expression and by shifting the En2 gradient rostrally (Lee et al., 1997) . Lastly, tissue loss in the midbrain-hindbrain region has been observed in mice carrying loss of function mutations in the Fgf8 gene (Meyers et al., 1998) . By extending the comparative analysis of Fgf8 and Fgf17 expression in this tissue to stages that have not been previously examined, we have identi®ed unique temporal and spatial expression patterns. These differences in expression suggest unique roles for these two genes in midbrain-hindbrain development. For example, Fgf17 is expressed in the midbrainhindbrain junction after E12.5 when Fgf8 expression is no longer detectable. Fgf17 may therefore have a predominant role at later stages of midbrain development. At stages earlier than E12.5, the broader expression domain of Fgf17 may also contribute quantitatively to an FGF morpho-genic gradient. Interestingly, the spatial and temporal differences in Fgf8 and Fgf17 expression described here are reminiscent of that seen for En1 and En2 and Pax2 and Pax5, genes also expressed in the midbrain-hindbrain junction (Joyner, 1996) . Mice lacking En1 develop an earlier midbrain-hindbrain phenotype than En2 null mutants (Joyner et al., 1991; Wurst et al., 1994) , and double null mutants have an enhanced phenotype. Similarly, Pax2 null mice have early defects in neural tube closure in the midbrain-hindbrain region (Torres et al., 1996) while Pax5 null mice only have a small deletion of the posterior midbrain. Like En2 and Pax5, Fgf17 may function later in the development of the midbrain-hindbrain region at a time when Fgf8 is no longer expressed. In contrast, the predominant expression of Fgf8 compared to Fgf17 at E8.5, suggests a more important role for Fgf8 in early midbrain-hindbrain development.
An FGF signal is also proposed to be important for patterning the forebrain at early somite stages. It has been shown that a signal in the anterior neural ridge is important for maintaining the expression of Bf1, a transcription factor essential for forebrain development (Shimamura and Rubenstein, 1997) . Fibroblast growth factor 8 is suggested to be part of this signal because of its ability to maintain Bf1 expression in the absence of the anterior neural ridge. Our data shows that Fgf8 expression in the anterior forebrain is initiated earlier than Fgf17, suggesting a predominant role for FGF8 in the early stages of forebrain development and that such a role is shared by FGF17 after E9.5. The early role for FGF8 has been demonstrated by the loss of olfactory bulbs and dorsal midline structures of the forebrain in Fgf8 hypomorphic mice (Meyers et al., 1998) . The extent of cooperativity between FGF8 and FGF17 at later stages of forebrain development and the role of FGF8 in patterning the ventral hypothalamus remains to be addressed.
Regulation of vascular smooth muscle cell (VSMC) development by FGFs
Fibroblast growth factor 8 and FGF17 can activate the`c' splice form of FGFR2. During midgestation development, Fgf8, Fgf17 and Fgfr2 (Orr-Urtreger et al., 1993) are all expressed throughout the wall of the great vessels. Because of the co-expression of both FGF ligands and an appropriate FGFR, it is likely that FGF8 and FGF17 transmit a signal during vascular development. The observed higher level of Fgf17 expression suggests that this ligand may be particularly important in arterial development. In addition to Fgf8 and Fgf17, Fgf1, Fgf2 and Fgf7 have also been observed in (VSM) muscle (Winkles et al., 1996; Winkles et al., 1997) . However, the expression of these Fgfs has only been identi®ed in the adult suggesting that they may be involved in adult vascular physiology but not in development. Consistent with this, mice lacking Fgf2 are viable and do not develop vascular pathology (Zhou et al., 1998) . Furthermore, both FGF1 and FGF2 lack signal peptides suggesting that they may only be released following vascular injury and FGF7 may signal towards the endothelium which speci®-cally expresses Fgfr2b, a receptor highly speci®c for FGF7 (Orr-Urtreger et al., 1993; Ornitz et al., 1996; Winkles et al., 1997) .
Several lines of evidence support a role for FGF signaling in the regulation of VSM development. First, injection of mRNA encoding a dominant negative FGF receptor can delay the development of VSMCs in Xenopus embryos (Thiery and Koteliansky, 1994) . Second, lineage analysis studies in avian embryos have identi®ed two types of smooth muscle cells in large elastic arteries, both of which respond to FGF. One population originates within the cardiac neural crest and is of ectodermal origin and another arises from local mesenchyme (Le Lievre and Le Douarin, 1975) . Interestingly, the response of these cell populations to FGF is differentially modi®ed by TGFb 1 (Majesky, 1996) which enhances the response to FGF in neural crest derived VSMC but inhibits the response to FGF in mesoderm derived VSMC. This difference may account for the enriched neural crest-derived VSMC component in the aortic arch and its branches (Le Lievre and Le Douarin, 1975) .
Unlike skeletal muscle cells, the genetic program for VSM development is largely unknown. However, a recent study on the transcriptional regulation of a smooth muscle marker, SM22a , has identi®ed a cis-acting element in the promoter of this gene that can direct transgene expression speci®cally in arterial smooth muscle cells (Li et al., 1996a) . Because endogenous SM22a is expressed more broadly in multiple smooth muscle lineages, including venous and visceral VSMCs (Li et al., 1996b) , this study suggests that distinct transcriptional mechanisms may exist for regulating different genetic programs in visceral, venous and arterial VSMCs. Because Fgf17 expression is only detected in arterial VSMCs and not in visceral and venous VSMCs, our data provides further support for diversity in the genetic control of VSMC lineages.
Regulation of bone development by FGFs
The role of FGFs in skeletal development was revealed recently by the mapping of at least eight human skeletal disorders to FGF receptors 1, 2 and 3 (reviewed by Webster and Donoghue, 1997; . All of these disorders result from dominant point mutations and cause craniofacial, appendicular and/or axial bone abnormalities. Expression studies have localized Fgfrs 1, 2 and 3 to speci®c regions of the developing skeleton. The Fgf17 gene is expressed in hypertrophic chondrocytes and in the marrow space, Fgfr2 is expressed in perichondrium, periosteum and marrow space, and Fgfr3 is expressed in proliferating and prehypertrophic chondrocytes. The unique expression pattern of each receptor correlates with the phenotype associated with speci®c point mutations in FGFR 1, 2 and 3.
Despite recent advances in understanding the importance of FGF receptor signaling in skeletal development, the ligands that activate these receptors in developing bone and cartilage are not known. The Fgf2 gene is expressed in the growth plate of murine and bovine adult long bones (Twal et al., 1994) . However, its expression during embryonic skeletal development is not known and mice lacking Fgf2 do not develop skeletal abnormalities (Dono et al., 1998; Ortega et al., 1998; Zhou et al., 1998) . In this study, Fgf8 and Fgf17 mRNA was identi®ed in parts of the developing skeleton such as in costal cartilage, mandible and scapula. Expression of Fgf8, but not Fgf17, was observed in the growth plate of developing long bones. Signi®cantly, both FGF8 and FGF17 can activate FGFR2 and FGFR3. The expression of Fgf8 in the growth plate and Fgf8 and Fgf17 in costal cartilage makes these FGFs candidate ligands for FGFR3, which has been shown to negatively regulate chondrocyte proliferation and differentiation . Additionally, Fgf expression in the perichondrium and in intramembranous bone may provide a proliferating signal for osteoblast precursors acting through FGFR2. Notably, Fgfr2 expression is localized to proliferating preosteoblast cells in developing calvarial bones and is down-regulated upon the onset of differentiation (Iseki et al., 1997) .
Functional redundancy among FGF family members
Gene duplication events throughout evolution are likely to have contributed to the expansion of the Fgf family. Such duplication events are implicated by the observation of subfamilies of Fgfs with high degrees of similarity (Fig. 1A and Coulier et al., 1997) . The high degree of conservation of FGF sequence between species suggests that in addition to providing functional redundancy, unique roles for each FGF have evolved and have been maintained. Studies in which single and multiple members of the FGF family are mutated in mice will be needed to address these issues.
Experimental procedures
Identi®cation of Fgf17 cDNA and genomic clones
A 155-bp mouse Fgf17 cDNA was obtained by reverse transcription-PCR (RT-PCR) using mouse brain RNA. The primers (D0233, GCA AAG ACT GCG TGT TCA CGG AG and D0235, GAT GAA GTG GGC CTC GCG CTG) were designed based on a human Fgf17 EST sequence (Greene et al., 1998) and were chosen to lie within the predicted third exon based on the known structure of other members of the FGF family. Similarly, a forward primer located in exon 1D (JX74, CTC TAC AGC AGG ACC AGT GGC AAG CA) and a reverse primer in exon 3 (JX75, GAA GGC CGT GTA GTT CTC CAG T) were used to amplify a 260-bp mouse cDNA fragment which was subdoned into a pGEM5 T-vector (Promega Inc.) and used for RNase protection analysis. The same primer pair was also used to amplify a 2.0-kb genomic fragment from FVB/N mouse DNA. Genomic P1 clones (Genome Systems, St. Louis, MO) were identi®ed by PCR screening using a forward primer in exon 1D (JX88, TCT CCC CAA ACT GTC TGC GCT T) and a reverse primer located in the intron following exon 1D (JX79 ACG TGC AGG TCA CCG GAC GT). Genomic subclones were identi®ed by shotgun subcloning and hybridization to cDNA probes. Exon lA and lB and the 3 H portion of exon 1D and 3 H untranslated sequences were identi®ed by sequencing genomic subclones and aligning the genomic sequence with the human Fgf17 cDNA. To identify any alternatively spliced cDNAs a forward primer in the putative 5 H UTR (JX123 CCA GCT GAA TTC CTC AGT CTC TC) and a reverse primer in exon 1D GX124, CGC GTT GAC GTC CGG TGA CCT GCA) were used to amplify cDNA made from 11.5 day embryos. The 3 H coding sequence plus 83-bp of 3 H UTR (total 540-bp) was cloned by RT-PCR using a forward primer, JX79, and a reverse primer, JX101 (CCC CAT CTT TGG ATG AGT TAG A). The 5 H and 3 H cDNAs were sequenced and assembled using an AatII site in the overlapping region.
The sequence similarity tree was calculated using the Clustal V algorithm (Higgins et al., 1992) . All sequence analysis was performed using Geneworks software (Intelligenetics) on a Macintosh computer.
Chromosomal mapping of the mouse Fgf17 gene
Genomic DNA from the BSS backcross panel ((C57BL/ 6J £ SPRET/Ei) Fl £ SPRET=Ei) was purchased from the Jackson laboratory (Bar Harbor, ME). C57BL/6J and SPRET/Ei DNA were digested with several enzymes and analyzed by DNA blot hybridization with an Fgf17 cDNA probe to identify restriction fragment length polymorphisms (RFLPs). An XbaI digest revealed two bands with SPRET/ Ei DNA and only one with C57BL/6J DNA, suggesting the existence of an XbaI site in SPRET/Ei DNA that is not present in C57BL/6J DNA. A pair of PCR primers was designed to amplify a 2-kb genomic fragment containing the XbaI polymorphism. Based on the XbaI digestion pattern of the 2-kb ampli®ed genomic fragment, the distribution pattern of Fgf17 alleles was determined for the BSS panel and compared to the BSS data base to determine the relative map position of the Fgf17 gene (Rowe et al., 1994) .
NIH3T3 cell transformation and tumorigenesis assay
Full-length alternatively spliced cDNA isoforms of Fgf17, Fgf17a and Fgf17b were generated by RT-PCR, subcloned into the MIRB expression vector (Chellaiah et al., 1994) and transfected into NIH3T3 cells as previously described (MacArthur et al., 1995a) . The MIRB-FGF8b vector has been described previously (MacArthur et al., 1995a) .
For tumorigenesis assays, 5-week-old nude mice (nu/nu) were injected subcutaneously with 1 £ 10 6 cells suspended in 0.1 ml phosphate buffered saline. After injection, the animals were observed for the development of tumors over a period of 4 weeks.
RNase protection analysis
Total RNA was puri®ed from mouse embryos. Twenty micrograms of RNA was lyophilized prior to resuspension in 30 ml of hybridization buffer (40 mM piperazine-N,N Hbis[2-ethanesulfonic acid]) (PIPES) (pH 6.4), 400 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 80% formamide] which contained 0.5±5 £ 10 5 cpm of the appropriate [a 32 P]-UTP (800 mCi/mmol; New England Nuclear) transcribed probes. Samples were denatured at 958C for 5 min, then incubated at 508C for 8 h. Unhybridized probe was removed by adding 350 ml of RNase digestion buffer (10 mM Tris±HCl (pH 7.5), 300 mM NaCl, 5 mM EDTA, 14 mg RNase A, 248 units RNase T1) and incubating the reaction for 30 min at 308C. Duplex RNA hybrids were then puri®ed with RNAzol B (Teltest, Inc.), dried under vacuum, and resuspended in 8 ml of RNA loading buffer (1 mM EDTA, 0.1% bromophenol blue, 0.1% xylene cyanole FF, 80% formamide). Samples were denatured for 5 min at 958C, chilled on ice, and resolved on a 5% denaturing polyacrylamide gel (Long Ranger, J.T. Baker). Gels were dried under vacuum and exposed to Kodak Xomat ®lm.
In situ hybridization
The probe used to detect Fgf8 was a 600-bp fragment containing 420-bp of 3 H coding sequence and 180-bp of 3 H UTR. This probe shares 58% identity with the corresponding Fgf17 cDNA sequence. The probe used to detect Fgf17 was the 540-bp fragment discussed above, containing 457-bp of 3 H coding sequence and 83-bp of 3 H UTR. The Fgf17 probe shares 56% sequence identity with the corresponding Fgf8 cDNA sequence. Fresh frozen sections of mouse embryonic tissues were brie¯y ®xed in 4% paraformaldehyde, washed in PBS and ethanol and then air dried. Hybridization was carried out overnight at 55±608C with a 35 Slabeled RNA probe (2 £ 10 6 cpm/slide) diluted in 50 ml hybridization buffer (50% formamide, 10% dextran sulfate, 1 £ Denhardt's solution, 300 mM NaCl, 40 mM DTT, 150 mg/ml yeast tRNA and 300 mg/ml salmon sperm DNA). After hybridization, slides were washed at room temperature in 4 £ SSC for 15 min, 2 £ SSC for 15 min, 0.5 £ SSC for 5 min, followed by a 20 min wash in 0.1 £ SSC at 558C. Slides were then treated with 20±40 mg/ml RNase A at 378C for 30 min followed by rinses in 50%, 70% and 95% ethanol, and then dried in air. Sections were dipped in Kodak NBT-2 emulsion and exposed for 10±30 days at 48C. After developing in Kodak D19 and ®xing, slides were counterstained in hematoxylin and eosin. Sections were viewed using dark ®eld microscopy and all images were acquired with Kodak 320T color reversal ®lms.
